XML 33 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Revenues (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2019 and 2018:

			Three months ended September 30,																		Nine months ended September 30,
			2019						2018						2019						2018
Products:
Acetadote			$	777,185					$	1,122,544					$	2,608,160					$	3,238,284
Omeclamox-Pak			116,063						278,017						794,205						509,358
Kristalose			2,924,237						3,017,803						9,720,434						9,490,901
Vaprisol			224,940						(67,436)						724,143						1,712,353
Caldolor			1,170,567						1,318,109						3,543,166						3,458,881
Ethyol			3,299,136						2,593,830						8,398,564						7,659,594
Totect			137,344						45,249						373,150						727,211
Vibativ			1,451,595						—						6,156,653						—
Other			270,851						184,414						1,536,790						447,277
Total net revenues			$	10,371,918					$	8,492,530					$	33,855,265					$	27,243,859

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration